Anti-Thymocyte Globulin (Equine)

Breastfeeding
  • TRADE NAME: Atgam (Pfizer)
  • INDICATIONS: Management of allograft rejection in renal transplant patients, prophylaxis of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation
  • CLASS: Immunosuppressant
  • HALF-LIFE: 3–9 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: C

Contraindicated in patients who have had a severe systemic reaction during prior administration of any equine gamma globulin preparation.

Our database has 22 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
LOCAL
OTHER


Page last updated 03/16/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric